The revenue beat and raised guidance are strong positives for the growth narrative, but the EPS miss and widening adjusted EBITDA loss indicate heavy investment spending. Traders should watch next quarter's revenue trajectory and cash burn rate for signs of operating leverage. The stock may trade on the revenue beat and guidance initially, but sustained profitability remains a key overhang.
Price Chart
Executive Summary
Kestra Medical Technologies reported Q4 FY2026 revenue of $28.6M (+66% YoY), beating consensus of $26.5M, but EPS of -$0.67 missed the -$0.58 estimate by 15.5%. Gross margin expanded to 54.8% from 44.3% and FY2027 revenue guidance of $137M (+44%) was raised. The revenue beat and strong guidance signal accelerating adoption of the ASSURE wearable defibrillator, though widening GAAP losses and cash burn temper the outlook.
Key Financial Metrics
Key Facts
- Q4 FY2026 revenue $28.6M, +66% YoY, vs consensus $26.5M (beat by 8.1%)
- GAAP EPS -$0.67 vs consensus -$0.58 (miss by 15.5%)
- Gross margin expanded to 54.8% from 44.3% YoY
- FY2027 revenue guidance raised to $137M, representing 44% growth over FY2026
- GAAP net loss widened to $38.8M from $51.1M in prior year Q4 (improvement on absolute basis but still negative)
- Adjusted EBITDA loss widened to $26.7M from $20.3M in prior year Q4
- Cash and investments $262.2M as of April 30, 2026
Financial Impact
Revenue beat of ~$2.1M (8.1%) vs consensus; FY2027 guidance of $137M implies 44% YoY growth; EPS miss of $0.09 per share
Risk Factors
- Continued GAAP net losses and negative free cash flow ($81.7M operating cash used in FY2026)
- Competitive pressure in the wearable cardioverter defibrillator market from ZOLL and others
- Dependence on commercial expansion and reimbursement dynamics
- High share-based compensation ($33.6M in FY2026) diluting shareholders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3327235 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Insider Cluster | $28.76 | awaiting T+20 | — | $29.42 (+2.29%) |
Oct 20, 2026 6d ago | 144 | $27.31 | awaiting T+20 | — | $29.42 (+7.73%) |
Oct 20, 2026 6d ago | ANALYST-UPGRADE | $28.28 | awaiting T+20 | — | $29.42 (+4.03%) |
Sep 30, 2026 26d ago | 144 | $27.12 | awaiting T+20 | — | $29.42 (+8.50%) |
Sep 14, 2026 6w ago | Press Release | $25.18 $26.97 | ▲ +7.11% | ▲ +4.39% | $29.42 (+16.84%) |
Sep 10, 2026 6w ago | Insider Cluster | $22.85 $26.98 | ▲ +18.07% | ▲ +16.21% | $29.42 (+28.75%) |
Sep 10, 2026 6w ago | Press Release | $23.57 $25.77 | ▲ +9.33% | ▲ +7.21% | $29.42 (+24.82%) |
Aug 31, 2026 8w ago | Press Release | $25.12 $28.29 | ▲ +12.62% | ▲ +12.30% | $29.42 (+17.12%) |
Aug 26, 2026 8w ago | Press Release | $26.57 $25.76 | ▼ −3.05% | ▼ −3.27% | $29.42 (+10.73%) |
Aug 11, 2026 10w ago | Insider Cluster | $28.00 $23.57 | ▲ +15.82% | ▲ +13.92% | $29.42 (−5.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers